Skip to content
10-Q/A

Quarterly Report

ABVC BioPharma, Inc. ABVC

0001213900-26-023062

← back to feed
Filed
Mar 3, 2026 12:00 AM ET
Period of report
Amendment. Amends a previously filed report.
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Mar 3, 2026 25.44M sh
Shares Diluted Q3 2025 · Sep 30, 2025 23.26M sh
Shares Diluted Q3 2025 · Sep 30, 2025 18.57M sh
Shares Diluted Q3 2025 · Sep 30, 2024 12.41M sh
Shares Diluted Q3 2025 · Sep 30, 2024 11.16M sh
Operating Cash Flow restated Q3 2025 · Sep 30, 2025 −$2.4M
Operating Cash Flow restated Q3 2025 · Sep 30, 2024 −$1.11M
Short Term Debt Q3 2025 · Sep 30, 2025 $809.1K
Short Term Debt Q3 2025 · Dec 31, 2024 $840.25K
Short Term Debt restated Q3 2025 · Sep 30, 2024 $896.25K
Short Term Investments Q3 2025 · Sep 30, 2025 $65.18K
Short Term Investments Q3 2025 · Dec 31, 2024 $64.74K
Cash And Equivalents Q3 2025 · Sep 30, 2025 $192.07K
Cash And Equivalents Q3 2025 · Dec 31, 2024 $248.38K
Stockholders Equity restated Q3 2025 · Sep 30, 2025 $12.06M
Stockholders Equity Q3 2025 · Dec 31, 2024 $1.23M
Stockholders Equity restated Q3 2025 · Sep 30, 2024 $1.64M
Current Liabilities restated Q3 2025 · Sep 30, 2025 $6.54M
Current Liabilities Q3 2025 · Dec 31, 2024 $6.56M
Current Liabilities restated Q3 2025 · Sep 30, 2024 $6.25M
Total Liabilities restated Q3 2025 · Sep 30, 2025 $6.72M
Total Liabilities Q3 2025 · Dec 31, 2024 $6.82M
Total Liabilities restated Q3 2025 · Sep 30, 2024 $6.44M
Current Assets restated Q3 2025 · Sep 30, 2025 $3.31M
Current Assets Q3 2025 · Dec 31, 2024 $2.18M
Current Assets restated Q3 2025 · Sep 30, 2024 $2.17M
Total Assets restated Q3 2025 · Sep 30, 2025 $21.21M
Total Assets Q3 2025 · Dec 31, 2024 $7.54M
Total Assets restated Q3 2025 · Sep 30, 2024 $7.78M
Eps Diluted restated Q3 2025 · Sep 30, 2025 −$0.09
Eps Diluted restated Q3 2025 · Sep 30, 2025 −$0.28
Eps Diluted restated Q3 2025 · Sep 30, 2024 −$0.03
Eps Diluted restated Q3 2025 · Sep 30, 2024 −$0.37
Eps Basic restated Q3 2025 · Sep 30, 2025 −$0.09
Eps Basic restated Q3 2025 · Sep 30, 2025 −$0.28
Eps Basic restated Q3 2025 · Sep 30, 2024 −$0.03
Eps Basic restated Q3 2025 · Sep 30, 2024 −$0.37
Sga Expense Q3 2025 · Sep 30, 2025 $798.25K
Sga Expense Q3 2025 · Sep 30, 2025 $2.1M
Sga Expense restated Q3 2025 · Sep 30, 2024 $557.6K
Sga Expense restated Q3 2025 · Sep 30, 2024 $1.95M
Rd Expense Q3 2025 · Sep 30, 2025 $29.89K
Rd Expense Q3 2025 · Sep 30, 2025 $92.03K
Rd Expense Q3 2025 · Sep 30, 2024 $37.83K
Rd Expense Q3 2025 · Sep 30, 2024 $147.29K
Net Income restated Q3 2025 · Sep 30, 2025 −$2.04M
Net Income restated Q3 2025 · Sep 30, 2025 −$5.14M
Net Income restated Q3 2025 · Sep 30, 2024 −$394.77K
Net Income restated Q3 2025 · Sep 30, 2024 −$4.17M
Operating Income restated Q3 2025 · Sep 30, 2025 −$1.96M
Operating Income restated Q3 2025 · Sep 30, 2025 −$4.95M
Operating Income restated Q3 2025 · Sep 30, 2024 −$302.32K
Operating Income restated Q3 2025 · Sep 30, 2024 −$4M
Gross Profit Q3 2025 · Sep 30, 2024 $388.98K
Gross Profit Q3 2025 · Sep 30, 2024 $506.86K
Cost Of Revenue Q3 2025 · Sep 30, 2024 $296
Cost Of Revenue Q3 2025 · Sep 30, 2024 $763
Revenue Q3 2025 · Sep 30, 2024 $389.28K
Revenue Q3 2025 · Sep 30, 2024 $507.62K